Morgan Stanley Reiterates Overweight on Neurocrine Biosciences, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a $130 price target.
August 04, 2023 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Neurocrine Biosciences and maintained a $130 price target.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Neurocrine Biosciences. The maintained price target of $130 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100